Livzon Pharmaceutical: A-share buyback progresses, H-share repurchases yet to begin

As of September 30, 2025, Livzon Pharmaceutical Group has repurchased 15,376,845 A-shares through concentrated bidding, representing 1.70% of the company's total share capital. The highest price paid was RMB 41.99 per share and the lowest was RMB 33.21 per share. The total capital used for these repurchases amounts to RMB 570,228,471.25, excluding transaction fees.

This A-share repurchase aligns with the company's previously approved plan to repurchase shares for cancellation to reduce registered capital. The approved plan allowed for a total repurchase amount between RMB 60,000,000.00 and RMB 100,000,000.00, with a repurchase price not exceeding RMB 45.00 per share. The A-share repurchase program was initially approved on December 24, 2024, and its continued implementation was approved on May 29, 2025.

Regarding H-share repurchases, the company has not yet conducted any repurchases under the general mandate granted by the board of directors as of September 30, 2025. These H-share repurchases are intended to be conducted via the Stock Exchange of Hong Kong Limited at a price not exceeding 5% of the average closing price of the preceding five trading days, also for the purpose of cancelling shares to reduce registered capital.